Genentech's Perjeta gets boost from final CLEOPATRA data
This article was originally published in Scrip
Roche/Genentech's humanized HER-2 targeting MAb Perjeta (pertuzumab) is set for a sales boost after final data from its Phase III CLEOPATRA study showed that it increased survival by 16 months when used in combination with Herceptin (trastuzumab) and docetaxel chemotherapy in previously untreated patients with HER-2 positive metastatic breast cancer.
You may also be interested in...
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.